Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk says weekly IcoSema superior to daily insulin glargine, aspart
08:34am, Monday, 08'th Jan 2024
Denmark's Novo Nordisk said on Monday its COMBINE 3 phase 3a drug trial had shown that a weekly injection of IcoSema was superior in controlling blood sugar level in people with type 2 diabetes compar
Novo Nordisk (NVO) Up on $1.1B Research Deals With 2 Biotechs
12:02pm, Friday, 05'th Jan 2024
Novo Nordisk (NVO) gains 4% after signing $1.1 billion research collaboration agreements with two biotech companies to develop novel treatment approaches for cardiometabolic diseases.
Equity CEFs/ETFs: Top Picks For 2024 - Part II
11:01am, Friday, 05'th Jan 2024
In Part I of my Top Picks For 2024, I explained why we saw such extreme valuation losses in most equity CEFs in 2023 and what that could-mean for 2024. In my opinion, liquidity was the over-riding fac
Global Giants: 3 Multinational Corporations to Outperform in 2024
06:53pm, Thursday, 04'th Jan 2024
Global stocks are an excellent way to get exposure to emerging growth markets like India. Another advantage is their diversification across geographic regions, which promotes revenue stability.
Why Novo Nordisk Stock Crushed the Market Today
06:08pm, Thursday, 04'th Jan 2024
The pharmaceutical company has two new research partners. It signed separate but similar deals with Omega Therapeutics and Cellarity.
Pharma Stock Surges on New Drug Partnerships
02:41pm, Thursday, 04'th Jan 2024
Stocks are fighting tooth and nail to stay in positive territory today, as the sluggish start to 2024 continues.
Novo Nordisk Stock Hit a Record on Thursday. Here's Why.
02:25pm, Thursday, 04'th Jan 2024
Shares of Novo Nordisk (NVO), the market leader in weight-loss drugs, jumped more than 4% Thursday after the company said it inked research agreements with two American biotech firms.
Is the January Effect reliable indicator for yearly performance?
10:21am, Thursday, 04'th Jan 2024
The S&P 500 and other major indexes are getting off to a slow start to kick off the new year. Some of 2023's leading stocks including Tesla Inc. NASDAQ: TSLA, Norwegian Cruise Line Holdings Ltd.
Ozempic parent Novo Nordisk enters collaboration agreements with Omega and Cellarity on new treatments for obesity management
06:23am, Thursday, 04'th Jan 2024
Novo Nordisk NVO, +1.48% NOVO.B, +1.88% said Thursday it has entered research collaboration agreements with Omega Therapeutics Inc. OMGA, -8.08% and Cellarity on new treatments for obesity management.
Wegovy maker Novo Nordisk signs research partnerships with U.S. biotech firms
06:03am, Thursday, 04'th Jan 2024
Blockbuster weight-loss drug maker Novo Nordisk announced on Thursday research collaborations with two U.S. biotech firms, part of its efforts to stay ahead in big pharma's race to develop more treatm
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
07:33pm, Wednesday, 03'rd Jan 2024
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $103.62, denoting a +1.48% change from the preceding trading day.
Novo Nordisk faces number of overlooked trends including competition for Wegovy, warns investment bank
08:01am, Wednesday, 03'rd Jan 2024
Novo Nordisk (NYSE:NVO) was the European stock market success of last year, on the back of its anti-obsecity drug Wegovy/Ozempic, but analysts at Jefferies wonder if the valuation may be nearing the
Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly
06:12am, Tuesday, 02'nd Jan 2024
Spending on anti-obesity medication is increasing, with some individuals spending more on medication than on food. Novo Nordisk's semaglutide drug, sold as Wegovy, is in high demand and the company is
7 Investments To Avoid In 2024
07:00am, Monday, 01'st Jan 2024
7 Investments To Avoid In 2024
Your New Year's Resolution For 2024: Invest $10,000 In These 5 Stocks
02:54pm, Friday, 29'th Dec 2023
I review the stocks of five world-class companies that I am convinced will bring me closer to my ambitious goal of being able to fund my living expenses through dividends.
